GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Nepal Journals Online (JOL)  (4)
  • 1
    Online Resource
    Online Resource
    Nepal Journals Online (JOL) ; 2010
    In:  SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS Vol. 5, No. 2 ( 2010-05-07), p. 1-5
    In: SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS, Nepal Journals Online (JOL), Vol. 5, No. 2 ( 2010-05-07), p. 1-5
    Abstract: Introduction: Co-management of tuberculosis (TB) and HIV is complicated by pharmacologic drug interactions between rifampicin (RMP) and certain classes of antiretroviral agents. The NNRTIs Nevirapine (NVP) or Efavirenz (EFV), used to HIV infection, are known to induce the CYP 450 enzyme system. Thus when RMP is co-administered along with NVP or EFV, the bioavailability of RMP could be lowered leading to drug resistance and treatment failure. Objectives: To study the steady state pharmacokinetics of RMP in HIV and HIV-TB patients receiving antiretroviral regimens containing NVP or EFV respectively. Methods: The study population comprised of HIV and HIV-TB patients undergoing antiretroviral treatment with NVP and EFV containing regimens respectively. These patients were also receiving concomitant RMP. Rifampicin was estimated by HPLC in blood collected at different time points after drug administration. The pharmacokinetic variables of RMP were calculated using WinNonlin software. Results & Conclusions: Co-administration of NVP or EFV did not alter the pharmacokinetics of RMP in HIV and HIV-TB patients, suggesting that the dose of RMP need not be altered during antiretroviral treatment with NVP or EFV. Key words: Rifampicin; nevirapine; efavirenz; drug-drug interactions; HIV-TB DOI: 10.3126/saarctb.v5i2.3068 SAARC J. Tuber. Lung Dis. HIV/AIDS 2008 Vol.5(2) 1-5
    Type of Medium: Online Resource
    ISSN: 2091-0959 , 1818-9741
    Language: Unknown
    Publisher: Nepal Journals Online (JOL)
    Publication Date: 2010
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Nepal Journals Online (JOL) ; 2010
    In:  SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS Vol. 5, No. 2 ( 2010-05-07), p. 6-9
    In: SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS, Nepal Journals Online (JOL), Vol. 5, No. 2 ( 2010-05-07), p. 6-9
    Abstract: Aims: To study single dose pharmacokinetics of lamivudine (3TC) in healthy subjects. Methods: Twelve healthy subjects were administered 3TC (150 mg) followed by timed blood and urine collections up to 24 hours. Pharmacokinetic variables and percent dose of 3TC in urine were calculated. Results: Plasma exposure and percent dose of 3TC in urine were highly correlated (p 〈 0.001; r = 0.96). 3TC concentration at 24 hours was undetectable in all study subjects. Conclusions: Timed urine measurements could be used to study bioavailabilty of 3TC. Plasma 3TC measurements could be used to monitor adherence among HIV-infected patients on antiretroviral treatment. Key words: lamivudine; plasma; urine; compliance to treatment   DOI: 10.3126/saarctb.v5i2.3069 SAARC J. Tuber. Lung Dis. HIV/AIDS 2008 Vol.5(2) 6-9
    Type of Medium: Online Resource
    ISSN: 2091-0959 , 1818-9741
    Language: Unknown
    Publisher: Nepal Journals Online (JOL)
    Publication Date: 2010
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Nepal Journals Online (JOL) ; 2017
    In:  SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS Vol. 14, No. 1 ( 2017-07-12), p. 27-32
    In: SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS, Nepal Journals Online (JOL), Vol. 14, No. 1 ( 2017-07-12), p. 27-32
    Abstract: Introduction: Levofloxacin (LFX) is one of the second line anti-tuberculosis drugs used in the treatment of multi drug resistant tuberculosis. Monitoring of LFX concentrations in plasma may be valuable to study its pharmacokinetics and drug-drug interaction when co-administered with other anti-tuberculosis drugs. We developed a high performance liquid chromatic method of determination of LFX in plasma.Methodology: The method involved deproteinisation of the sample with perchloric acid and analysis of the supernatant using a reversed-phase C18 column (150mm) and fluorescence detection at an excitation wavelength of 290 nm and an emission wavelength of 460 nm.Results: The assay was specific for LFX and linear from 0.25 to 10.0μg/ml. The relative standard deviation of intra- and inter-day assays was lower than 10%. The average recovery of LFX from plasma was 99%.Conclusion: A sensitive, specific and validated method for quantitative determination of LFX in plasma was developed .Due to its simplicity; the assay can be used for pharmacokinetic studies of LFX.SAARC J TUBER LUNG DIS HIV/AIDS, 2017; XIV(1), page: 27-32
    Type of Medium: Online Resource
    ISSN: 2091-0959 , 1818-9741
    Language: Unknown
    Publisher: Nepal Journals Online (JOL)
    Publication Date: 2017
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Nepal Journals Online (JOL) ; 2012
    In:  SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS Vol. 9, No. 1 ( 2012-10-18), p. 13-18
    In: SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS, Nepal Journals Online (JOL), Vol. 9, No. 1 ( 2012-10-18), p. 13-18
    Abstract: Introduction: Treatment of tuberculosis (TB) requires a combination of drugs. Isoniazid (INH) and pyrazinamide (PZA) are key components of the fi rst-line regimen used in the treatment of TB and monitoring these drug levels in plasma would help in better patient care. The objective of the study is to develop and validate a simple and rapid high performance liquid chromatographic method for simultaneous determination of INH and PZA in human plasma. Methodology: The method involved deproteinisation of plasma with para hydroxy benzaldehyde and trifl uoroacetic acid and analysis using a reversed-phase C8 column and UV detection at 267nm. The fl ow rate was set at 1.5 ml/min at ambient temperature. The accuracy, linearity, precision, specifi city, stability and recovery of the method were evaluated. The method was applied to estimate plasma INH and PZA collected from six children with TB. Results: Well resolved peaks of PZA and INH at retention times of 3.2 and 6.1 minutes respectively were obtained. The assay was linear from 0.25 - 10.0 ìg/ml for INH and 1.25 – 50.0 ìg/ml for PZA. The within-day and between-day relative standard deviation for standards were below 10%. The average recoveries of INH and PZA from plasma were 104 and 102% respectively. Conclusions: A rapid and accurate method for simultaneous determination of INH and PZA in plasma was validated. The assay spans the concentration range of clinical interest. The easy sample preparation and small sample size makes this assay highly suitable for pharmacokinetic studies of INH and PZA in TB patients. SAARC Journal of Tuberculosis, Lung Diseases & HIV/AIDS 2012; IX (1) 13-18 DOI: http://dx.doi.org/10.3126/saarctb.v9i1.6960
    Type of Medium: Online Resource
    ISSN: 2091-0959 , 1818-9741
    Language: Unknown
    Publisher: Nepal Journals Online (JOL)
    Publication Date: 2012
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...